§ 1.

The aim and purpose of NMPN is to promote better treatment for patients with the myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis. This is to be achieved through the performance of phase I-II studies of new treatment modalities and randomized phase III-IV trials in collaboration with other European working groups. Another important part of NMPN:s work is preclinical in vitro studies of different aspects of the myeloproliferative disorders. Finally, evidence based clinical care programmes will be updated on a regular basis. The activities of the NMPN are performed by different subgroups that are formed for each project.

§ 2.

NMPN holds major meetings every 6 months. These meetings are open to any clinician or scientist with an interest in the myeloproliferative neoplasms. Between meetings the chairman and the scientific secretary are responsible for the follow-up of decisions taken at meetings.

§ 3.

NMPN is led by a chairman and a scientific secretary. These are elected by the group with a mandate of three years. The same person(s) can be re-elected if the group so decides. An election group with one member from each country has the responsibility to suggest candidates.

§ 4.

NMPN has members from Denmark, Finland, Iceland, Norway and Sweden.

§ 5.

The activities of NMPN are currently financed by unrestricted research grants from pharmaceutical companies, Applications for research grants from different other sources will be submitted on a regular basis. NMPN:s financial account is currently located at Uppsala University/Academic Hospital. The chairman is responsible for the account.

§ 6.

New protocols, suggestions concerning the election of chairman and/or secretary, changes in guidelines or bylaws should be distributed to the members of NMPN at least one month before the next major meeting of the group.